Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    steven hancock | Prostate Cancer
Previous Study | Return to List | Next Study

Assessment of 3D Transperineal Ultrasound Imaging w/ Matrix Array Transducers in Prostate Radiotherapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02432820
Recruitment Status : Terminated (Business decision)
First Posted : May 4, 2015
Last Update Posted : April 10, 2017
Sponsor:
Collaborator:
Philips Healthcare
Information provided by (Responsible Party):
Stanford University

Brief Summary:

SPECIFIC STUDY AIMS

  1. To evaluate congruence between pelvic anatomical structures segmented on MRI and/or CT scans co-registered with transperineal US scans acquired with an optically and/or electromagnetically tracked matrix array ultrasound transducer.
  2. To estimate the achievable accuracy of anatomy tracking based on 3D US matrix-array transducer imaging and grey-level based image registration algorithms.

Condition or disease
Prostate Cancer

Detailed Description:

SPECIFIC STUDY AIMS

  1. To evaluate congruence between pelvic anatomical structures segmented on MRI and/or CT scans co-registered with transperineal US scans acquired with an optically and/or electromagnetically tracked matrix array ultrasound transducer.
  2. To estimate the achievable accuracy of anatomy tracking based on 3D US matrix-array transducer imaging and grey-level based image registration algorithms.

Layout table for study information
Study Type : Observational
Actual Enrollment : 7 participants
Observational Model: Case-Only
Time Perspective: Cross-Sectional
Official Title: Assessment of 3D Transperineal Ultrasound Imaging With Matrix Array Transducers as a Potential Imaging Modality for Adaptive Prostate and Post-Prostatectomy Radiotherapy
Study Start Date : April 2015
Actual Primary Completion Date : September 30, 2016
Actual Study Completion Date : September 30, 2016

Resource links provided by the National Library of Medicine





Primary Outcome Measures :
  1. Changes in dose-volume histogram (DVH) indices in prostate images [ Time Frame: 1 year ]
    The overall purpose of this study is to evaluate the ability of 3D ultrasound (US) to visualize the prostate with sufficient clarity and reliability to monitor and model anatomy motion and deformation. If this research study is successful in its findings, this mode of ultrasound imaging will have the ability to be adapted for the purposes of cost-efficient prostate radiotherapy.

  2. Changes in dose-volume histogram (DVH) indices in bladder images [ Time Frame: 1 year ]
    The overall purpose of this study is to evaluate the ability of 3D ultrasound (US) to visualize the bladder with sufficient clarity and reliability to monitor and model anatomy motion and deformation. If this research study is successful in its findings, this mode of ultrasound imaging will have the ability to be adapted for the purposes of cost-efficient prostate radiotherapy.

  3. Changes in dose-volume histogram (DVH) indices in rectal wall images [ Time Frame: 1 year ]
    The overall purpose of this study is to evaluate the ability of 3D ultrasound (US) to visualize the rectal wall with sufficient clarity and reliability to monitor and model anatomy motion and deformation. If this research study is successful in its findings, this mode of ultrasound imaging will have the ability to be adapted for the purposes of cost-efficient prostate radiotherapy.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Prostate cancer patients being treated at Stanford Cancer Center
Criteria

Inclusion Criteria:

  • Men that will undergo prostate radiotherapy as a primary treatment or post-prostatectomy.
  • Age 18 or older
  • Ability to understand and sign informed consent

Exclusion Criteria:

  • Younger than 18 yrs old
  • Inability to provide written and spoken consent.
  • Patients with implanted actively controlled devices that may be subject to electromagnetic interference from the UroNav/PervuNav electromagnetic tracking used in the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02432820


Locations
Layout table for location information
United States, California
Stanford University, School of Medicine
Stanford, California, United States, 94305
Sponsors and Collaborators
Stanford University
Philips Healthcare
Investigators
Layout table for investigator information
Principal Investigator: Dimitre Hristov Stanford University
Principal Investigator: Steven Hancock Stanford University

Layout table for additonal information
Responsible Party: Stanford University
ClinicalTrials.gov Identifier: NCT02432820     History of Changes
Other Study ID Numbers: PROS0070
33012
First Posted: May 4, 2015    Key Record Dates
Last Update Posted: April 10, 2017
Last Verified: April 2017
Keywords provided by Stanford University:
Prostate Cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Genital Diseases, Male
Prostatic Diseases